Prof. Linghua Li | Cancer Science | Best Researcher Award

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

🌟Linghua Li, Ph.D., M.S., B.S. 🌍

Head Director, Infectious Disease Center
Guangzhou Eighth People’s Hospital, Guangzhou Medical University

👩‍⚕️Biography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth People’s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

  • National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
  • Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
  • NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

  • ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Li’s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

🧬Key Areas of Expertise

🔬 HIV Prevention and Treatment
🌿 Opportunistic Infections
📊 Clinical Trials and Data Analysis
🧑‍⚕️ Internal and Infectious Diseases

📚Academic Background

  • B.S., Clinical Medicine, Medical School of Peking University (1997)
  • M.S., Internal Medicine, Sun Yat-sen University (2008)
  • Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
  • Visiting Scholar, UNC-Chapel Hill (2012)
  • Visiting Scholar, Duke University (2014)

🔬Research Impact

🌟 Over 20 funded research projects
📄 Numerous publications in infectious disease and public health journals
📚 Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. 🌏✨

✨ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. 🌟🌍

📊🔬NOTABLE PUBLICATION:
  • Utilizing Protein–Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19
    • Authors: Peiyan Zheng, Baolin Liao, Jiao Yang, Hu Cheng, Zhangkai Cheng, Huimin Huang, Wenting Luo, Yiyue Sun, Qiang Zhu, Yi Deng, et al.
    • Journal: Microorganisms
    • Year: 2023

Prof Dr.Ronny Priefer – Cancer Biomarkers – Best Researcher Award

Prof Dr.Ronny Priefer - Cancer Biomarkers - Best Researcher Award

MCPHS University - United States

AUTHOR PROFILE

Scopus 

Orcid

EARLY ACADEMIC PURSUITS

Ronny Prieger's academic journey began with a Bachelor of Science degree in Chemistry from the University of Northern British Columbia. He then pursued his passion for organic chemistry, earning a Ph.D. from McGill University in Montreal, Quebec. His early academic pursuits laid a solid foundation for his future endeavors in the field of medicinal chemistry.

PROFESSIONAL ENDEAVORS

After completing his Ph.D., Ronny Prieger joined Neurochem Inc. in Saint-Laurent, Quebec, Canada, as a Post-Doctoral Fellow. This position provided him with valuable industry experience and exposure to neurochemistry research.Subsequently, Prieger transitioned into academia, where he served as an Associate Dean of Graduate Studies at the School of Pharmacy, Massachusetts College of Pharmacy and Health Science University (MCPHS) in Boston. He also held the position of Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences at MCPHS, further solidifying his role in academia.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER BIOMARKERS

Throughout his career, Ronny Prieger has made significant contributions to the field of medicinal chemistry. His research focus spans various areas, including neurochemistry, cancer biomarkers and organic chemistry. Prieger's work has contributed to advancing our understanding of drug development and neurodegenerative diseases.

IMPACT AND INFLUENCE

Prieger's contributions have had a notable impact on both academia and industry. His research findings have been instrumental in shaping the direction of medicinal chemistry research, particularly in the development of novel therapeutics for neurological disorders.

ACADEMIC CITATIONS

Ronny Prieger's research has garnered attention within the academic community, as evidenced by the numerous citations his work has received in scholarly publications. His contributions to the field have been recognized and cited by peers and colleagues, further solidifying his reputation as a respected researcher in medicinal chemistry.

LEGACY AND FUTURE CONTRIBUTIONS

As an established figure in the field of medicinal chemistry, Ronny Prieger's legacy extends beyond his current endeavors. His dedication to research and education has inspired future generations of scientists and pharmaceutical professionals. Moving forward, Prieger continues to make significant contributions to the field, with a focus on advancing drug discovery and improving treatments for neurological disorders.

NOTABLE PUBLICATIONS

Layer-by-layer assembly: A versatile approach for tailored biomedical films and drug delivery. 2024

A comparison of continuous glucose monitors (CGMs) in diabetes management: A systematic literature review. 2023

Comparison of small molecules VEGFR inhibitors in the treatment of renal cell carcinoma. 2023

Challenges Related to Extractables/Leachables During Bioprocessing. 2023

Detection technologies of volatile organic compounds in the breath for cancer diagnoses. 2023 (4)